Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the (“EANM”), which is being held in Hamburg, Germany, from October 19-23, 2024. Presentations regarding certain of the Company’s other assets, including results based on investigator-initiated use of certain of those assets, will also be made at EANM.
Descriptions of these presentations are provided in the table below. The abstract book is available online at .
| Presenter | Abstract Title | Presentation Details |
| Perspective Update on PSV-359 | ||
| Brianna S. Cagle, PhD | Preclinical evaluation and first-in-human imaging of [203/212Pb]Pb-PSV359, a novel cyclic peptide targeting fibroblast activation protein-alpha (FAP) | Abstract ID: OP-473 Session Type: Oral Presentation Session: Featured Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: FAP Therapies: Mechanisms and Response Session Date: Monday, October 21, 2024 Session Time: 6:05 PM |
| Perspective Update on VMT-α-NET | ||
| D. Liu, PhD | Impact of molar activity on [203Pb]Pb-VMT-α-NET biodistribution profile in mice bearing neuroendocrine tumor xenograft | Abstract ID: OP-020 Session Type: Oral Presentation Session: Featured Session: Translational Molecular Imaging & Therapy Committee + Radiopharmaceutical Sciences Committee: Tracer (Pharmaco) Kinetics Session Date: Sunday, October 20, 2024 Session Time: 8:00 AM |
| Investigator-Led Research on VMT-α-NET | ||
| Dharmender Malik | Interim results of 212Pb-VMT-α-NET Targeted Alpha Therapy in Metastatic Gastro-entero-pancreatic Neuroendocrine Tumors: First In-human Clinical Results on Safety and Efficacy | Presentation #: OP-256 Session #: 611 Session Title: Theranostics Track - TROP Session: Oncology & Theranostics Committee: Neuroendocrine Therapy Session Date: Sunday, October 20, 2024 Session Time: 4:45-6:15 PM Session Hall: Hall Y1-Y3 |
| Dharmender Malik | Image guided evaluation of 212Pb-VMT-α-NET in metastatic Neuroendocrine tumors: Bio distribution and Dosimetry | ePoster #: EP-0929 Session #: EP-58 |
| Investigator-Led Preclinical Research | ||
| Dongyoul Lee | Evaluation and Design of New Chelators using Density Functional Theory Modeling: Implications for Improved Performance of 203Pb/212Pb-based Theranostic for Cancers | ePoster #: EP-0993 Session #: EP-62 |
| Jung Woo Byun | Development of 203Pb Labeled SSTR-Targeting Peptides as Surrogates for 212Pb Labeled Radiopharmaceuticals | ePoster #: EP-0102 Session #: EP-04 |
PSV359
The Company will present updated preclinical data on PSV359, a novel cyclic peptide targeting fibroblast activation protein-alpha (FAP) and a molecular linker to a lead-specific chelator.
An oral presentation combining first-in-human SPECT/CT images generated by an independent investigator using [203Pb]Pb-PSV359, along with updated analysis of preclinical studies of [212Pb]Pb-PSV359 conducted by the Company, will be presented.
[212Pb]VMT-α-NET for the Treatment of Neuroendocrine Tumors (NETs)
The Company has been informed that two updated analyses based on investigator-led clinical research of [212Pb]VMT-α-NET in India have been accepted for presentation by the EANM conference. The investigator enrolled adult patients with histologically confirmed gastroenteropancreatic neuroendocrine tumors (“GEP-NETs”) and metastatic medullary thyroid carcinomas. The most recent prior public update of this patient series was during the Society of Nuclear Medicine & Molecular Imaging ("SNMMI") Annual Meeting in .
- The investigator informed the Company that an oral presentation will be provided on the GEP-NET patients as of a later cut-off date than the cut-off date for the SNMMI conference. The analysis presented at SNMMI was based on 10 GEP-NET patients plus 3 patients with other SSTR2+ tumors as of a data cutoff date of May 31, 2024.
- An ePoster to be presented at the conference will focus on the biodistribution and image-guided dosimetric estimates of the [212Pb]VMT-α-NET. Dosimetry data presented during SNMMI was based on two patients.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
For more information, please visit the Company's website at .
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include express or implied statements concerning, among other things, the Company's ability to pioneer advanced treatment applications for cancers throughout the body; expectations regarding the timing and advancement of the Company's clinical and preclinical programs; the FAP binding affinity and specificity of [203/212Pb]Pb-PSV-359; the ability of the Company's proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides; the opportunity to personalize treatment and optimize patient outcomes using the Company's complementary imaging diagnostics that incorporate the same targeting peptides; the Company's expectation that its "theranostic" approach enables the ability to see specific tumors and then treat them to potentially improve efficacy and minimize toxicity; the Company's ability to develop a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations; expectations regarding the potential market opportunities for the Company's product candidates; the potential functionality, capabilities, and benefits of the Company's product candidates and the potential application of these product candidates for other disease indications; the Company's expectations, beliefs, intentions, and strategies regarding the future; the Company's intentions to improve important aspects of care in cancer treatment; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at . Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Perspective Therapeutics IR: Annie Cheng Russo Partners, LLC Nic Johnson
